LoadingLoadingLoadingThe quick read
Latest quote·Oct 16
Net selling: insiders sold $8.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $16K to $65K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNet selling: insiders sold $8.2M and bought $0 of ABBV stock on the open market in the 90 days to Oct 18, 2026, according to SEC Form 4 filings. The largest was Donoghoe, Nicholas (EVP, Chief Bus/Strat Officer), who sold $8.2M. The latest filing was on Aug 18, 2026.
Rep. Pete Sessions (R) sold $15K to $50K on Sep 14, 2026, disclosed 4 days later. Rep. Josh Gottheimer (D) sold $1K to $15K on May 5, 2026, disclosed 29 days later. In total, 2 members disclosed 2 ABBV trades with trade dates in the last 180 days, filed a median 17 days after trading.
This summary uses filings available on Oct 18, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position and insiders have been net selling.
Buys/Adds (3)
Citadel
$691.0M
added
D.E. Shaw
$382.7M
added
AQR
$313.8M
added
Sells (1)
Donoghoe Nicholas
$8.2M
sold
Sells (2)
No tracked top-trader positions in ABBV right now.
Live Hyperliquid positioning - not every stock is covered
Last report
Jul 31, 2026
Financial period
Q2
Adjusted EPS
$3.61 expected
Revenue
$16.76B expected
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 31, 2026 | $3.65 / $3.61Yahoo Finance | +1.15% beat | $16.99B / $16.76B | +1.36% beat |
| Mar 31, 2026 | Apr 29, 2026 | $2.65 / $2.67Yahoo Finance | -0.77% in line | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 4, 2026 | $2.71 / $2.65Yahoo Finance | +2.16% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Oct 31, 2025 | $1.86 / $1.78Yahoo Finance | +4.23% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Jul 31, 2025 | $2.97 / $2.91Alpha Vantage | +2.06% beat | Unavailable | Unavailable |
| Mar 31, 2025 | Apr 25, 2025 | $2.46 / $2.40Alpha Vantage | +2.50% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Jan 31, 2025 | $2.16 / $2.12Alpha Vantage | +1.89% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Oct 30, 2024 | $3.00 / $2.92Alpha Vantage | +2.74% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Estimates as of Oct 18, 2026
EPS expected
$3.77 to $3.87
Revenue expected
18 analysts
Last 30 days
Analysts cutting estimates
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $15.78B | $16.62B | $15.00B | $16.99B |
| Cost of what it sold | $5.30B | $4.55B | $4.22B | $4.29B |
| Gross profit | $10.47B | $12.07B | $10.78B | $12.70B |
| What it spent | ||||
| Research and development | $2.32B | $2.58B | $2.47B | $2.34B |
| Sales and admin | $3.57B | $3.90B | $3.58B | $3.63B |
| Other operating costs | $2.68B | -$217.0M | — | $291.0M |
| Total operating expenses | $8.57B | $6.26B | $6.05B | $6.27B |
| What was left | ||||
| Operating profit | $1.90B | $5.81B | $4.73B | $6.43B |
| Interest on debt | $739.0M | $714.0M | $717.0M | $746.0M |
| Profit before tax | $714.0M | $2.67B | $1.04B | $4.28B |
| Tax | $526.0M | $853.0M | $342.0M | $662.0M |
| Net profit | $186.0M | $1.82B | $699.0M | $3.61B |
| EBITDA | $3.52B | $5.37B | $3.69B | $8.61B |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Lilly, Merck, AbbVie Stocks Surge. Why Healthcare Is Rallying Today.
BullishOct 14How Phase 2 Lupus Data At Biogen (BIIB) Has Changed Its Investment Story
NeutralOct 14AbbVie Inc Stock (ABBV) Moved Up by 3.36% on Oct 14: A Full Analysis
BullishOct 14AbbVie stock hits all-time high at 283.44 USD By Investing.com
BullishOct 14AbbVie Rises on Fresh SKYRIZI Data and Supportive Analyst Tone
BullishOct 14Texas Instruments options signal 7.1% move on earnings
NeutralOct 14Did SKYRIZI’s Subcutaneous Crohn’s Data Just Shift AbbVie’s (ABBV) Immunology Investment Narrative?
Leans bullishOct 14AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Leans bearishOct 14